UNSPSC 51433935: Manidipine dihydrochloride

This classification denotes a calcium channel blocker with the molecular formula C35H38N4O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZL507UZ6QL, chemically known as 2-(4-(diphenylmethyl)-1-piperazinyl)ethyl methyl (+/-)-1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinecarboxylate dihydrochloride, but more generally known as manidipine dihydrochloride, which bears US NIH Compound Identifier 150762.

European Medicines Agency schedules manidipine dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08641MIG. Most nations, for tariff purposes, schedule manidipine dihydrochloride under HS 29335995. SMILES: CC1=C(C(C(=C(N1)C)C(=O)OCCN2CCN(CC2)C(C3CCCCC3)C4CCCCC4)C5CCCC(C5)[N+](=O)[O-])C(=O)OC.CL.CL.

UNSPSC 51433935 Manidipine dihydrochloride is a Commodity code designating a specific pharmaceutical ingredient, but recent state and local opportunities tagged under this code reflect broader pharmaceutical and medication procurement rather than manidipine specifically. State and local governments are actually soliciting emergency medical supplies, generic multi-source pharmaceuticals, and over-the-counter products through this taxonomy entry. The issuing bodies span city fire and rescue departments, state health agencies, and cooperative purchasing alliances. The City of Tampa's Fire Rescue division solicits advanced life support medications including epinephrine, labetalol, adenosine, and diltiazem through sealed competitive bids; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models through information-gathering RFIs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issues formal RFPs for generic pharmaceuticals and OTC products distributed across multiple state and local member jurisdictions.

Recent activity spans Florida, Texas, Minnesota, and Oregon through MMCAP's multi-state purchasing vehicle. The most concrete opportunity is the City of Tampa's Bid No. 26-P-00188 for Advanced Life Support Medications, an IFB due April 8, 2026, with an estimated contract value of $40,000, a one-year initial term with two one-year renewal options, and a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation not to exceed $10,000. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products on January 20, 2026, with proposals due March 26, 2026, requiring vendors to supply through three authorized wholesalers with contracts effective July 1, 2026, and emphasizing price competitiveness (weighted at 75 percent of evaluation), cGMP certification, Drug Supply Chain Security Act compliance, and chargeback-system integration. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, represents early-stage market intelligence gathering for a potential direct-to-manufacturer prescription program but carries no committed budget or timeline for formal procurement.